TORL BioTherapeutics LLC is aiming for its latest fundraise to take it past the regulatory finish line with TORL-1-23, which it calls a first-in-class antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6) in platinum-resistant ovarian cancer. TORL-1-23 is part of a suite of ADCs it is developing for solid tumors, including one against Claudin 18.2 (CLDN18.2), the target of a recently approved Astellas Pharma, Inc. drug and a growing number of therapeutic candidates that include cell therapies.
TORL Looks To Break Ground In Growing Field Of Claudin-Targeting Drugs
The company announced a series B-2 financing of $158m that it plans to use for pivotal Phase II development of TORL-1-23, which it called a first-in-class agent.
More from Financing
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.